Articles by Francisco Sapunar
89 Imlunestrant With or Without Abemaciclib as First- and Second-Line Therapy in Advanced Breast Cancer (ABC): A Subgroup Analysis From the EMBER-3 Trial
ByPatrick Neven, MD, PhD,Andre Mattar,Antonio Llombart-Cussac,Giuseppe Curigliano,Nadia Harbeck, MD, PhD,Joyce O’Shaughnessy, MD,François-Clément Bidard,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Cristina Saura,Lisa A. Carey, MD,Kamnesh R. Pradhan,Shanshan Cao,Monique Coersmeyer,Anna Emde,Francisco Sapunar,Komal L. Jhaveri,Philippe Aftimos 100 Imlunestrant Plus Abemaciclib Versus Fulvestrant Plus Abemaciclib in Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2–) Advanced Breast Cancer (ABC): An Indirect Treatment Comparison (ITC) of Three Phase 3 Trials
ByKomal L. Jhaveri,Francois Clement Bidard,Kevin Kalinsky, MD, MS,Patrick Neven, MD, PhD,Hope S. Rugo, MD,Sara M. Tolaney, MD, MPH,Lacey Litchfield,Christoph Cramer von Laue,Sory Traore,Francisco Sapunar,Yujia Li,Joyce O’Shaughnessy, MD
